What VCs Won't Let You Give Up to Pharma
This article was originally published in Start Up
Executive Summary
A VC will only object to deal structures which cap the upside for investors--a specific limited price, for example, in return for successfully developing an asset. If the deal leaves a residual element of upside, it could be just fine, even if it seems to take rights to an entire pipeline.
You may also be interested in...
Know Thy R&D Enemy: The Key to Fighting Attrition
By and large, drug companies have sharply reduced their emphasis on novel targets and, they assume, pipeline risk. But detailed analysis shows that more important risk-reducers are the molecular approach (biologics targeting novel mechanisms fail less frequently than small molecules targeting precedented mechanisms) therapeutic approach (targeted is less risky than broad), therapeutic area, and stage of development.
The Trouble with Spin-Offs
Drug firms have created relatively few venture-financed spin-offs. The central reason--the valuation impasse between VC and pharma--is as much pscyhologically rooted as financially.
Why Clinical Trials Fail Unexpectedly
Is there an explanation for the recent spate of biotech Phase II and Phase III clinical trial failures? It's almost impossible to give general reasons for specific clinical failures. Several hypotheses, borrowed from the tenets of behavioral finance, however, may help explain some recent, unanticipated later-stage setbacks. They may also support other studies that suggest that small biotech companies fail more often in clinical development than their larger biotech and pharma brethren.